Literature DB >> 9435298

HIV-1 protease inhibitors and the MDR1 multidrug transporter.

C G Lee, M M Gottesman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9435298      PMCID： PMC508565          DOI： 10.1172/JCI2575

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  13 in total

1.  Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

Authors:  A H Schinkel; U Mayer; E Wagenaar; C A Mol; L van Deemter; J J Smit; M A van der Valk; A C Voordouw; H Spits; O van Tellingen; J M Zijlmans; W E Fibbe; P Borst
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

2.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 3.  Biochemistry of multidrug resistance mediated by the multidrug transporter.

Authors:  M M Gottesman; I Pastan
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

4.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

Authors:  R B Kim; M F Fromm; C Wandel; B Leake; A J Wood; D M Roden; G R Wilkinson
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

5.  Is P-glycoprotein a sufficient marker for multidrug resistance in vivo? Immunohistochemical staining for P-glycoprotein in children and adult leukemia: correlation with clinical outcome.

Authors:  S Kaczorowski; M Ochocka; M Kaczorowska; R Aleksandrowicz; M Matysiakl; M Karwacki
Journal:  Leuk Lymphoma       Date:  1995-12

6.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Authors:  A H Schinkel; E Wagenaar; C A Mol; L van Deemter
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

7.  Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

Authors:  U Mayer; E Wagenaar; B Dorobek; J H Beijnen; P Borst; A H Schinkel
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

8.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

9.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

Authors:  A H Schinkel; J J Smit; O van Tellingen; J H Beijnen; E Wagenaar; L van Deemter; C A Mol; M A van der Valk; E C Robanus-Maandag; H P te Riele
Journal:  Cell       Date:  1994-05-20       Impact factor: 41.582

10.  Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype.

Authors:  D Drach; S Zhao; J Drach; R Mahadevia; C Gattringer; H Huber; M Andreeff
Journal:  Blood       Date:  1992-12-01       Impact factor: 22.113
View more
  12 in total

1.  No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients.

Authors:  Darinka Todorova Petrova; Petya Nedeva; Svilen Maslyankov; Svetoslav Toshev; Nikolay Yaramov; Srebrena Atanasova; Draga Toncheva; Michael Oellerich; Nicolas von Ahsen
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-03       Impact factor: 4.553

2.  Expression of P-glycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids.

Authors:  Anna M Wasilewska; Walentyna M Zoch-Zwierz; Mirosława Pietruczuk
Journal:  Eur J Pediatr       Date:  2006-12       Impact factor: 3.183

Review 3.  Human genetic variability and HIV treatment response.

Authors:  David W Haas
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

4.  Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.

Authors:  B M Sadler; C Gillotin; Y Lou; J J Eron; W Lang; R Haubrich; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors.

Authors:  Todd Hulgan; John P Donahue; Laura Smeaton; Minya Pu; Hongying Wang; Michael M Lederman; Kimberly Smith; Hernan Valdez; Christopher Pilcher; David W Haas
Journal:  Eur J Clin Pharmacol       Date:  2009-11       Impact factor: 2.953

6.  Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.

Authors:  Chantal Csajka; Catia Marzolini; Karin Fattinger; Laurent A Décosterd; Amalio Telenti; Jérôme Biollaz; Thierry Buclin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs.

Authors:  Kavitha S Rao; Maram K Reddy; Jayme L Horning; Vinod Labhasetwar
Journal:  Biomaterials       Date:  2008-08-28       Impact factor: 12.479

8.  Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters.

Authors:  R V Srinivas; D Middlemas; P Flynn; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 9.  Changing patterns in the neuropathogenesis of HIV during the HAART era.

Authors:  T D Langford; S L Letendre; G J Larrea; E Masliah
Journal:  Brain Pathol       Date:  2003-04       Impact factor: 6.508

10.  Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.

Authors:  Qing Ma; Alan Forrest; Susan L Rosenkranz; Michael F Para; Kevin E Yarasheski; Richard C Reichman; Gene D Morse
Journal:  Biopharm Drug Dispos       Date:  2008-03       Impact factor: 1.627
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.